Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes

Authors: Zhang Y, Shi R, Yu L, et al.
Published in Diabetes Ther 2020
The aim of this retrospective cohort study was to develop a risk nomogram for NAFLD in a Chinese population with T2DM. A questionnaire survey, physical examination and biochemical indicator testing were performed on 874 patients with T2DM...
Read MoreEstablishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes

Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH

Authors: Povero D, Yamashita H, Ren W, et al.
Published in Hepatol Commun 2020
For many years, double-layer phospholipid membrane vesicles, released by most cells, were not considered to be of biological significance. This stance has dramatically changed with the recognition of extracellular vesicles (EVs) as carriers of biologically active molecules that can traffic to local or distant targets and execute defined biological functions...
Read MoreCharacterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH

Left ventricular diastolic dysfunction in liver transplantation: a stronger association with non-alcoholic steatohepatitis

Authors: Marella HK, Kamal F, Peravali R, et al.
Published in Clin Exp Hepatol 2020
Cardiovascular death is an important cause of mortality in end stage liver disease patients undergoing orthotopic liver transplant. Left ventricular diastolic dysfunction is often the early manifestation of cirrhotic cardiomyopathy. In order to understand the risk factors for ventricular diastolic dysfunction in end stage liver disease patients...
Read MoreLeft ventricular diastolic dysfunction in liver transplantation: a stronger association with non-alcoholic steatohepatitis

Determining the reliability of liver biopsies in NASH clinical studies

Authors: Longerich T, Schirmacher P.
Published in Nat Rev Gastroenterol Hepatol 2020
The topic of liver biopsy in clinical studies, such as for treatments for NASH, is highly important. Despite limitations, liver biopsy remains the gold standard for the study of liver disease. It is important for the exclusion of alternative diseases and co-morbidities such as autoimmune hepatitis or primary biliary cholangitis...
Read MoreDetermining the reliability of liver biopsies in NASH clinical studies

The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: a meta-analysis of eleven epidemiological studies

Authors: Hayat U, Siddiqui AA, Okut H, et al
Published in Ann Hepatol 2020
Coffee consumption may have a protective impact on NAFLD and liver fibrosis. However, the evidence from the previous studies is inconsistent. This study comprises two meta-analyses. The first meta-analysis summarizes the effect of coffee consumption on NAFLD in patients who did or did not drink coffee...
Read MoreThe effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: a meta-analysis of eleven epidemiological studies

Fructose stimulated de novo lipogenesis is promoted by inflammation

Authors: Todoric J, Di Caro G, Reibe S, et al.
Published in Nature Metabolism 2020
Excessive fructose intake causes dysbiosis and tight-junction proteins downregulation, resulting in intestinal-barrier deterioration and low-grade endotoxaemia. Fructose consumption stimulates hepatosteatosis and, when combined with other risk factors, can cause steatohepatitis and even hepatocellular carcinoma. It is well established...
Read MoreFructose stimulated de novo lipogenesis is promoted by inflammation

Obstructive sleep apnea and severity of NAFLD

Authors: Krolow GK, Garcia E, Schoor F, et al
Published in Eur J Gastroenterol Hepatol 2020
Obstructive sleep apnea (OSA) is associated with the development and evolution of NAFLD, independent of obesity or other shared risk factors. The OSA–NAFLD association is related to the degree of nocturnal hypoxaemia in OSA. Animal models have largely focused on intermittent hypoxia, a key manifestation of OSA...
Read MoreObstructive sleep apnea and severity of NAFLD

Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease

Authors: Kim D, Murag S, Cholankeril G, et al
Published in Clin Gastroenterol Hepatol 2020
D. Kim et al. (Stanford University School of Medicine, Stanford, California, United States) studied whether physical activity, measured by accelerometer, is associated with all-cause and cardiovascular mortality among individuals with NAFLD.
Read MorePhysical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease

Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population

Authors: Lind L, Johansson L, Ahlstrom H, et al
Published in World J Hepatol 2020
Several scores based on easily measurable biochemical and clinical parameters, including the fatty liver index (FLI), hepatic steatosis index (HSI), lipid accumulation product (LAP), and NAFLD liver fat score (LFS), have been developed for the detection of NAFLD. However, comparative information regarding the efficacy of these scores for predicting NAFLD...
Read MoreComparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Authors: Eslam M, Sanyal AJ, George J, et al.
Published in Gastroenterology 2020
The exclusion of other chronic liver diseases including “excess” alcohol intake are usually necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, “positive criteria” to diagnose the disease are required. A panel of international experts from 22 countries...
Read MoreMAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

From NAFLD to MAFLD: when pathophysiology succeeds

Authors: Tilg H, Effenberger M.
Published in Nat Rev Gastroenterol Hepatol 2020
Two new position papers convincingly propose that non-alcoholic fatty liver disease needs a new name — metabolic associated fatty liver disease (MAFLD). A new name for this disease affecting nearly one billion people globally is overdue, as knowledge gained from the past decades has definitely demonstrated that MAFLD is a purely metabolic disorder...
Read MoreFrom NAFLD to MAFLD: when pathophysiology succeeds

Non-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population.

Authors: Catanzaro R, Sciuto M, He F, et al.
Published in Acta Clin Belg 2020
Several studies have investigated the association between serum uric acid and metabolic syndrome / NAFLD. Four meta-analysis on retrospective and prospective studies confirmed this association, especially in women. However, most of the studies included in the analysis were performed on Asian populations. Despite high quality and large population...
Read MoreNon-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population.

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES